RESUMO
To determine if resistance/tolerance to the antischistosomal drug praziquantel (PZQ) is appearing in Egyptian villages within the Nile delta region, where it has been used extensively, we treated 1,607 infected villagers and observed that 321 required one additional treatment while 89 villagers required two additional treatments; 24 of the 89 were still not cured after a third dose of this drug. Eggs were isolated from fecal samples and serum was isolated from blood taken from seven villagers successfully treated after a single dose and from 14 villagers not successfully treated after two or three doses of PZQ. The eggs were used to establish infections in mice (isolates), which were then treated six weeks after infection with three different doses of PZQ. Serum was used to determine the concentration of PZQ in the infected humans. Three of the egg isolates from the 14 villagers that could not be treated with three doses of PZQ produced infections in mice that were statistically less responsive to PZQ when compared with isolates obtained from patients that were cured after a single dose of this drug. Pharmacokinetic parameters were the same in patients treated successfully after a single dose versus those not treated successfully following two or three doses, thus eliminating the possibility that poor cure rates among infected villagers was due to a decrease in PZQ bioavailability. From our data, approximately 1-2.4% of the villagers treated with PZQ could not be completely cured of their infection and three of every 1,000 treated villagers may harbor parasites that can tolerate high doses of PZQ. These results indicate that the extensive use of PZQ in the Nile delta region of Egypt has not resulted in a dramatic change in the efficacy of this drug. The isolation of schistosomes that are less susceptible to PZQ may be a warning signal that will require establishment of a monitoring system, similar to the one we have developed, to determine if the percentage of patients that cannot be cured by PZQ is increasing. Furthermore, if that percentage begins to increase over time, it will be critical to determine, by pharmacologic methods reported in this study, whether isolates obtained from uncured patients are becoming increasingly resistant to PZQ.
Assuntos
Praziquantel/farmacologia , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/farmacologia , Adulto , Animais , Antiplatelmínticos , Disponibilidade Biológica , Fatores de Confusão Epidemiológicos , Resistência a Medicamentos , Egito , Fezes/parasitologia , Feminino , Humanos , Imunocompetência , Masculino , Camundongos , Praziquantel/farmacocinética , Praziquantel/uso terapêutico , Distribuição Aleatória , Esquistossomose mansoni/imunologia , Esquistossomose mansoni/metabolismo , Esquistossomicidas/farmacocinética , Esquistossomicidas/uso terapêutico , CaramujosRESUMO
Recent evidence suggest that resistance to praziquantel (PZQ) may be developing. This would not be surprising in countries like Egypt where the drug has been used aggressively for more that 10 years. The classic phenotype of drug resistance is a significant increase in the 50% effective dose value of isolates retrieved from patients not responding to the drug. In a previous publication, we reported that such phenotypes have been isolated from humans infected with Schistosoma mansoni. Since the action of PZQ may be dependent upon the drug and host factors, most notably the immune system, we analyzed the quantitative effects of PZQ on single worms that differed in their response to PZQ when maintained in mice. Our hypothesis was that the in vitro action of the drug would correlate with it in vivo action. We confirmed this hypothesis and conclude that the in vitro action of the drug is related to its in vivo action. Knowing this relationship will assist in our ability to detect or survey for the PZQ resistant phenotype in human populations.
Assuntos
Praziquantel/farmacologia , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/farmacologia , Animais , Resistência a Medicamentos , Egito , Humanos , Fígado/parasitologia , Masculino , Veias Mesentéricas/parasitologia , Camundongos , Contração Muscular/efeitos dos fármacos , Praziquantel/uso terapêutico , Esquistossomicidas/uso terapêuticoAssuntos
Transportadores de Cassetes de Ligação de ATP/genética , DNA de Helmintos/genética , Schistosoma mansoni/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/química , Transportadores de Cassetes de Ligação de ATP/química , Sequência de Aminoácidos , Animais , Camundongos , Dados de Sequência Molecular , RNA Mensageiro/metabolismo , Homologia de Sequência de AminoácidosRESUMO
Praziquantel is the current drug of choice for human schistosomiasis. Recent reports from laboratory and field studies concerning reduced praziquantel efficacy against Schistosoma mansoni have generated some controversy. The prevailing question is whether the emergence of strains of schistosome resistant to praziquantel is a fact, or an artifact resulting from erroneous field or laboratory experimentation. In this article, Padraic Fallon, Liang-feng Tao, Magdi Ismail and James Bennett examine the available evidence for schistosome resistance to praziquantel. Contributory factors to the schistosomicidal activity of praziquantel, which may interfere with evaluation of drug efficacy or resistance, are also considered.
RESUMO
The in vitro uptake, cellular distribution, efflux, stability, and toxicity levels of an oligodeoxynucleotide phosphorothioate (PS-oligonucleotide) have been studied in mature Schistosoma mansoni worms. The intracellular accumulation of 35S-labeled PS-oligonucleotide occurred roughly in proportion to the worm body mass over a wide concentration range, whether the worms were exposed singly or in mating pairs. Cellular uptake was dependent on the extracellular concentration. A minor fraction (13%) of the PS-oligonucleotide taken up by the worm accumulated in the surface tegumental coat. Most of the PS-oligonucleotide taken up localized in the cytosol (54%) and the nuclei-enriched (33%) fractions. In a time course study on adult worms in culture, oligonucleotide uptake was observed within the first 2 h and peaked at about 36 h. A decrease in the intracellular concentration of the PS-oligonucleotide was observed by 42 h. Analysis of the extracted oligonucleotides showed that PS-oligonucleotide was digested slowly. Efflux of the oligonucleotide was time and temperature dependent. Significant toxicity to the cultured worms did not occur until the PS-oligonucleotide concentration was over 8 mg/ml (1 mM).
Assuntos
Oligodesoxirribonucleotídeos Antissenso , Oligonucleotídeos Antissenso/metabolismo , Schistosoma mansoni/metabolismo , Tionucleotídeos/metabolismo , Animais , Antivirais , Sequência de Bases , Técnicas de Cultura , Estabilidade de Medicamentos , Estudos de Viabilidade , Feminino , Cinética , Masculino , Dados de Sequência Molecular , Oligonucleotídeos Antissenso/toxicidade , Frações Subcelulares/metabolismo , Radioisótopos de Enxofre , Tionucleotídeos/toxicidadeRESUMO
A 7-year-old boy, who had returned to the United States in June 1991 after a 3-year stay in Malawi, was evaluated in October 1991 because of hematuria. He was excreting Schistosoma haematobium eggs and was treated with praziquantel (PZQ; approximately 40 mg/kg). He may have spit up < or = 30% of this dose, and a concomitant Giardia lamblia infection might have caused malabsorption of PZQ. Because of persistent excretion of viable eggs, he was retreated with PZQ in January and May 1992. Egg excretion was first quantified 2 months following his second course of PZQ; at that time it was 35 eggs per 10 mL of urine. He excreted viable eggs at least as late as October 1992, 5 months after his third PZQ course. Experimental administration of chemotherapy to hamsters infected with the S. haematobium strain demonstrated that it was susceptible to PZQ. Repeated courses of therapy with PZQ may be necessary to cure S. haematobium infection, and both parasite and host factors should be considered if infection persists.
Assuntos
Praziquantel/uso terapêutico , Esquistossomose Urinária/tratamento farmacológico , Animais , Criança , Humanos , Malaui , Masculino , Contagem de Ovos de Parasitas , Esquistossomose Urinária/diagnóstico , Viagem , Estados UnidosRESUMO
A cDNA encoding a Ca-ATPase homologue, designated SMA3, was isolated from an adult cDNA library of Schistosoma mansoni. The full-length cloned DNA contains a 3105-bp open reading frame that potentially encodes a 1035-amino-acid protein with a M(r) of 113,729 and a pl of 6.48. Homology searches for SMA3 reveal high sequence identity with a variety of Ca-ATPases from evolutionarily diverse organisms. SMA3 is predicted to contain 10 transmembrane regions typical of this protein family as well as other conserved domains, such as the phosphorylation site and FITC binding domain. The greatest sequence identity (40-50%) is found to those Ca-ATPases belonging to the secretory pathway subclass. Identification of the 5' end of the SMA3 cDNA by RACE analysis reveals the presence of a 36-base spliced leader RNA, suggesting that the SMA3 pre-mRNA is processed by trans-splicing. Northern analysis reveals a single dominant transcript of 5 kb in adult RNA preparations. Antibodies raised against an amino terminal peptide detect the protein in the adult tegument, suggesting that SMA3 functions to help control Ca homeostasis within the tegument and may play a role in signal transduction at the host parasite interface.